Association of Independent Prognostic Factors and Treatment Modality With Survival and Recurrence Outcomes in Breast Cancer

Nguyen, Dat; Yu, John S.; Reinhold, William C.; Yang, Sherry X.

doi:10.1001/jamanetworkopen.2020.7213

Cited by 23 publications

(22 citation statements)

References 43 publications

(83 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As in our study, Nguyen et al observed, on 956 patients treated in hospitals of four geographical regions of the United States, an increased risk of mortality with increasing age, except for patients younger than 40 years [33].…”

Section: Discussionsupporting

confidence: 85%

See 1 more Smart Citation

Impact of molecular subtype on 1325 early-stage breast cancer patients homogeneously treated with hypofractionated radiotherapy without boost: Should the indications for radiotherapy be more personalized?

et al. 2021

View full text Add to dashboard Cite

Aim: We report molecular subtype impact on 1325 early breast cancer (BCa) patients treated with whole breast hypofractionated (WBH) adjuvant forward-planned intensity modulated radiotherapy (F-IMRT) without boost. Methods and materials: From 02/2009-05/2017 1325 patients with pTis-pT3, pNx-N1aM0 BCa who underwent breast conservation surgery were treated with WBHF-IMRT in our institute, to a total dose of 40 Gy/15 fractions, without boost. Median age: 62 (interquartile range-IQR-:51.14e70.53) years. Histology: 8% in situ carcinoma (ISC), 92% invasive tumors. Molecular subtypes (invasive tumors): 49.9% Luminal A, 33.1% Luminal B Her2 negative (À), 6.2% Luminal B Her2 positive (þ), 3.6% Hormone Receptor (HR)-Her2þ, 7.1% Triple negative (TNBC), and 0.2% HRþ. Chemotherapy (CT) was prescribed in 28% of patients, hormonal therapy in 80.3%, monoclonal antibodies (MAb) in 86.8% of Luminal B Her2þ and 97.7% of HR-Her2þ patients. Results: Median follow up was 72.43 (IQR: 44.63e104.13) months. The 5-year Kaplan-Meier estimates of local relapse-free survival (LRFS) was 97.8%, regional-(RRFS) 98.6%, loco-regional-(LRRFS) 96.9%, distant-(DRFS) 96.6%, disease-free survival (DFS) 94.8% and overall survival (OS) 95.5%. Considering molecular subtypes, 5-year LRFS was: 99.8% for Luminal A, 96.7% for Luminal B Her2-, 94.1% for Luminal B Her2þ, 87.9% for HR-Her2þ, 95.1% for TNBC and 99.1% for in situ carcinoma. Conclusion: While the overall estimated probability of LR within 5 years after WBHF-IMRT without boost is good (2.2%), molecular subtypes have a strong impact, despite MAb therapy in Her2þ patients, and CT for TNBC patients, and could be used as a parameter in deciding the boost prescription.

show abstract

Section: Discussionsupporting

confidence: 85%

“…The following factors: tumor size, presence and number of positive lymph nodes, high-grade, hormonal and chemo-therapy were found to influence relapse free survival (LRRFS, DRFS, DFS, OS), an observation similar to that of other studies with a large number of patients [18,19,33].…”

Section: Discussionsupporting

confidence: 83%

Impact of molecular subtype on 1325 early-stage breast cancer patients homogeneously treated with hypofractionated radiotherapy without boost: Should the indications for radiotherapy be more personalized?

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The reasons for these differences are most probably the different molecular characteristics related to the molecular subtypes. A recent study investigating clinical prognostic factors including TP53 status, grade, size, node positivity, ER and HER2 status, and age found that only nodal status was significantly associated with chemotherapy outcomes [36] . Combined, these results suggest that ultimately molecular and not clinical features will enable the prediction of response for chemotherapy in breast cancer.…”

Section: Discussionmentioning

confidence: 99%

Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer

Győrffy

2021

Computational and Structural Biotechnology Journal

1,206

913

View full text Add to dashboard Cite

show abstract

“…In most cases, consistent results across studies are lacking, warranting further research on the subject before molecular biomarkers can be useful in selecting patients with NSCLC and being included in treatment algorithms for antiangiogenic agents. However, important advances are being made in other cancer types, including breast cancer, in which a recent study has found an association of independent prognostic factors with specific treatments and has weighted them by the outcome category (51).…”

Section: Discussionmentioning

confidence: 99%

Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study

et al. 2021

View full text Add to dashboard Cite

Finding angiogenic prognostic markers in advanced non-small-cell lung cancer is still an unmet medical need. We explored a set of genetic variants in the VEGF-pathway as potential biomarkers to predict clinical outcomes of patients with non-small-cell lung cancer treated with chemotherapy plus bevacizumab. We prospectively analyzed the relationship between VEGF-pathway components with both pathological and prognostic variables in response to chemotherapy plus bevacizumab in 168 patients with non-squamous non-small-cell lung cancer. Circulating levels of VEGF and VEGFR2 and expression of specific endothelial surface markers and single-nucleotide polymorphisms in VEGF-pathway genes were analyzed. The primary clinical endpoint was progression-free survival. Secondary endpoints included overall survival and objective tumor response. VEGFR-1 rs9582036 variants AA/AC were associated with increased progression-free survival (p = 0.012 and p = 0.035, respectively), and with improved overall survival (p = 0.019) with respect to CC allele. Patients with VEGF-A rs3025039 harboring allele TT had also reduced mortality risk (p = 0.049) compared with the CC allele. The VEGF-A rs833061 variant was found to be related with response to treatment, with 61.1% of patients harboring the CC allele achieving partial treatment response. High pre-treatment circulating levels of VEGF-A were associated with shorter progression-free survival (p = 0.036). In conclusion, in this prospective study, genetic variants in VEGFR-1 and VEGF-A and plasma levels of VEGF-A were associated with clinical benefit, progression-free survival, or overall survival in a cohort of advanced non-squamous non-small-cell lung cancer patients receiving chemotherapy plus antiangiogenic therapy.

show abstract

Association of Independent Prognostic Factors and Treatment Modality With Survival and Recurrence Outcomes in Breast Cancer

Abstract: This prognostic study identifies independent clinical and molecular measurements associated with overall and recurrence-free survival by homogeneous treatment in patients with breast cancer.

Cited by 23 publications

References 43 publications

Impact of molecular subtype on 1325 early-stage breast cancer patients homogeneously treated with hypofractionated radiotherapy without boost: Should the indications for radiotherapy be more personalized?

Impact of molecular subtype on 1325 early-stage breast cancer patients homogeneously treated with hypofractionated radiotherapy without boost: Should the indications for radiotherapy be more personalized?

Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer

Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study

Contact Info

Product

Resources

About